comprehensive -WSS

comprehensive

author：entertainment 2025-09-28 15:21:05 - browse：8

Boxes of Wegovy — pharma coverage from STAT — Carsten Snejbjerg/Bloomberg

LONDON — The investment arm of Novo Nordisk’s parent foundation is buying drug manufacturer Catalent in a $16.5 billion deal, an acquisition that will give Novo additional sites as it builds up production of its booming obesity and diabetes drugs.

Under the deal, Novo Holdings is purchasing Catalent, a major contract development and manufacturing company with more than 50 sites globally. In turn, Novo Nordisk is buying three of Catalent’s fill-finish sites from the investment group for $11 billion. Novo Holdings manages the assets of the Novo Nordisk Foundation, which has a controlling stake in the pharmaceutical company.

Catalent has been involved in the production of Novo’s obesity treatment Wegovy. With the agreement, Novo will pick up sites that focus on filling drugs in Italy, Brussels, and Bloomington, Ind. All have already been doing work for Novo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Devoted Health’s losses in Medicare Advantage persist

explore

WSS

Devoted Health’s losses in Medicare Advantage persist

Readout LOUD: Venture capital, Gilead, and more M&A

Genentech weighs delaying cancer therapy after drug pricing law

A single Democrat is willing to weaken Medicare negotiation power

AI gets buy

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

leisure time

comprehensive

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

Johnson & Johnson sued for allegedly overpaying for workers' drugs

Novavax promises a turnaround & Lilly roils the obesity market

Devoted Health’s losses in Medicare Advantage persist

Hepatitis C has a cure — but many Americans still lack access to it

Johnson & Johnson sued for allegedly overpaying for workers' drugs

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Where are patients getting their prescriptions for GLP

Trump demands the U.S. pay no more for drugs than other countries … again

What’s missing from the debate over nursing home staff minimums

leisure time

Large hospital system sues Multiplan for low

Genentech weighs delaying cancer therapy after drug pricing law

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

GOP presidential candidates start declaring their loyalty

Who are the detained American citizens released from prison in Iran?

AI gets buy

knowledge

explore

leisure time

hotspot